After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer
pharmaphorum
DECEMBER 23, 2022
This alone causes expense for cash-strapped hospitals and puts pressure on nursing and medical staff while they manage the side effects. Inobrodib works by targeting twin cancer proteins p300 and CBP, which impacts the expression of cancer drivers including MYC and IRF4. Side effects and cost implications.
52 
Let's personalize your content